Advertisement

Topics

Classen Immunotherapies, Inc. Company Profile

18:47 EDT 21st September 2017 | BioPortfolio

Tel: 410-377-8526


News Articles [182 Associated News Articles listed on BioPortfolio]

Vaccines, not Diet, are Causing Epidemic of Obesity and Type 2 Diabetes According to New Paper from Classen Immunotherapies

MANCHESTER, Md., June 26, 2017 /PRNewswire/ -- A newly published paper in June's Journal of Endocrinology, Diabetes & Obesity, 5(3): 1107, by immunologist J. Bart Classen, MD of Classen ...

Vaccines, Not Diet, Are Causing Epidemic Of Obesity And Type 2 Diabetes According To New Paper From Classen Immunotherapies Inc.

  Life Sciences Jobs   ...

President Trump Challenged by Immunologist J. Bart Classen, MD of Classen Immunotherapies to Stop Dangerous Vaccine Policies

MANCHESTER, Md., June 29, 2017 /PRNewswire-USNewswire/ -- J. Bart Classen, MD  (www.vaccines.net) of Classen Immunotherapies has written the following letter on immunization policy to Presid...

Keytruda success a crowning moment for cancer immunotherapies, but are more on their way?

With so much of the exciting data at ASCO 2017 again surrounding cancer immunotherapies, The Pharma Letter…

Immunotherapies Center Stage at EADV

The designated hot topic of this year's European Academy of Dermatology and Venereology (EADV) Congress will have specialists talking about the latest developments in immunotherapies. Medscape Medic...

Norwegian Biotech Hits €21M in Private Placement for its Immunotherapies

Targovax has raised €21M (NOK200M) in a private placement, which the biotech will use to fund data read-outs from clinical trials and CMC development. Targovax, based in Oslo, is developing a number...

Takeda and Shattuck Labs partner to develop immunotherapies for cancer treatments

Takeda Pharmaceutical has entered a research collaboration with Shattuck Labs to study and develop checkpoint fusion proteins that have the potential to be used as highly differentiated, advanced immu...

Takeda strikes partnership to develop single-drug cancer combo immunotherapies

Japanese pharma giant Takeda has announced that it is to partner up with US-based Shattuck Labs in a collaboration to develop checkpoint fusion proteins which can be refined and utilised as highly dif...

Drugs and Medications [0 Results]

None

PubMed Articles [104 Associated PubMed Articles listed on BioPortfolio]

Oncology pharma costs to exceed $150 billion by 2020.

Worldwide costs of oncology drugs will rise above $150 billion by 2020, according to a report by the IMS Institute for Healthcare Informatics. Many factors are in play, according to IMS, including the...

Oral and Sublingual Immunotherapy: Potential Causes for Eosinophilic Gastrointestinal Disorders?

Food allergy is a common health problem worldwide, with increasing prevalence during recent decades. The only approved treatments for food allergy are food avoidance and administration of emergency me...

T Cell-Associated Immunotherapy for Hepatocellular Carcinoma.

Hepatocellular carcinoma (HCC) is one of the most common malignant diseases worldwide with limited therapeutic options. Accumulating evidences suggest that immunotherapy could be a promising option fo...

Neurological Complications of Immunotherapies-Beware of the Checkpoint Ahead.

Immunologic approaches for the treatment of multiple myeloma.

The FDA approval of two monoclonal antibodies in 2015has heralded a new era of targeted immunotherapies for multiple myeloma (MM). In this review we discuss the recent approaches using different immun...

Clinical Trials [20 Associated Clinical Trials listed on BioPortfolio]

A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies

This is a Phase 1b/2 dose-optimization study to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of avelumab (MSB0010718C) in combination with other ...

Interest of Anti-telomerase T CD4 Immune Responses for Predicting the Effectiveness of Immunotherapies Targeting PD1 / PDL1

Recent scientific advances have shown the important role of immune system against cancer. Today, many immunological biotherapy like anti-PD1/PDL-1 are available in cancer treatment and gen...

GI-4000 With Adoptive Transfer in Pancreatic Cancer

The purpose of this study is to determine if it is safe to add multiple immunotherapies to standard chemotherapy and radiation for treating pancreatic cancer tumors that cannot be complete...

A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma

This research study is studying a pair of immunotherapies as a possible treatment for malignant pleural mesothelioma. The drugs involved in this study are: - Durvalumab ...

COMparison Between All immunoTherapies for Multiple Sclerosis.

The overarching goal of this study is to determine whether rituximab (RTX) offers effectiveness and safety advantages over other commonly used approved Disease-Modifying Drugs (DMT) in the...

Companies [42 Associated Companies listed on BioPortfolio]

Classen Immunotherapies, Inc.

Tel: 410-377-8526

CTL ImmunoTherapies

CTL ImmunoTherapies, located in Chatsworth, California, is a biotechnology company focusing on the discovery, development and manufacturing of theraputic vaccines.

Advaxis, Inc. and Rodman & Renshaw, LLC

Advaxis is a biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform tech...

Selexis SA and OSE Immunotherapeutics SA

Our ambition is to become a world leader in activation and regulation immunotherapies: OSE Immunotherapeutics is a biotechnology company led by world-class immunologists and focus...

Turnstone Biologics

Turnstone Biologics is a clinical-stage, immuno-oncology company focused on the development of next-generation oncolytic viral immunotherapies for patients with a broad range of s...

More Information about "Classen Immunotherapies, Inc." on BioPortfolio

We have published hundreds of Classen Immunotherapies, Inc. news stories on BioPortfolio along with dozens of Classen Immunotherapies, Inc. Clinical Trials and PubMed Articles about Classen Immunotherapies, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Classen Immunotherapies, Inc. Companies in our database. You can also find out about relevant Classen Immunotherapies, Inc. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record